Vonjo is a drug owned by Cti Biopharma Corp. It is protected by 3 US drug patents filed in 2022 out of which none have expired yet. Vonjo's patents will be open to challenges from 28 February, 2026. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 25, 2030. Details of Vonjo's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US8980873 | 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt |
Mar, 2030
(5 years from now) | Active |
| US8153632 | Oxygen linked pyrimidine derivatives |
Jan, 2029
(4 years from now) | Active |
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9573964 | Oxygen linked pyrimidine derivatives |
May, 2028
(3 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Vonjo's patents.
Latest Legal Activities on Vonjo's Patents
Given below is the list of recent legal activities going on the following patents of Vonjo.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| transaction for FDA Determination of Regulatory Review Period | 14 Mar, 2024 | US9573964 |
| transaction for FDA Determination of Regulatory Review Period | 29 Feb, 2024 | US9573964 |
| Second letter to regulating agency to determine regulatory review period | 30 Sep, 2023 | US9573964 |
| Letter from FDA or Dept of Agriculture re PTE application | 28 Sep, 2023 | US9573964 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 31 Aug, 2022 | US8980873 |
| Initial letter Re: PTE Application to regulating agency | 01 Jul, 2022 | US9573964 |
| Change in Power of Attorney (May Include Associate POA) Critical | 19 Jan, 2022 | US9573964 |
| Email Notification Critical | 19 Jan, 2022 | US9573964 |
| Email Notification Critical | 18 Jan, 2022 | US8980873 |
| Change in Power of Attorney (May Include Associate POA) Critical | 18 Jan, 2022 | US8980873 |
FDA has granted several exclusivities to Vonjo. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Vonjo, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Vonjo.
Exclusivity Information
Vonjo holds 2 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2029. Details of Vonjo's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 28, 2027 |
| Orphan Drug Exclusivity(ODE-397) | Feb 28, 2029 |
US patents provide insights into the exclusivity only within the United States, but Vonjo is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Vonjo's family patents as well as insights into ongoing legal events on those patents.
Vonjo's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Vonjo's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Mar 25, 2030 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Vonjo Generics:
There are no approved generic versions for Vonjo as of now.
About Vonjo
Vonjo is a drug owned by Cti Biopharma Corp. It is used for treating myelofibrosis by inhibiting Janus Associated Kinase 2 (JAK2). Vonjo uses Pacritinib Citrate as an active ingredient. Vonjo was launched by Cti Biopharma Corp in 2022.
Approval Date:
Vonjo was approved by FDA for market use on 28 February, 2022.
NCE-1 date:
NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Vonjo is 28 February, 2022, its NCE-1 date is estimated to be 28 February, 2026.
Active Ingredient:
Vonjo uses Pacritinib Citrate as the active ingredient. Check out other Drugs and Companies using Pacritinib Citrate ingredient
Treatment:
Vonjo is used for treating myelofibrosis by inhibiting Janus Associated Kinase 2 (JAK2).
Dosage:
Vonjo is available in capsule form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 100MG BASE | CAPSULE | Prescription | ORAL |